SynopsisHerpes zoster afflicts millions of older adults annually worldwide and causes significant suffering due to acute and chronic pain, or postherpetic neuralgia (PHN). Herpes zoster is caused by the reactivation of varicella-zoster virus (VZV) in sensory ganglia in the setting of age, disease and drug-related decline in cellular immunity to VZV. VZV-induced neuronal destruction and inflammation causes the principal problems of pain, interference with activities of daily living and reduced quality of life in older adults. To address these problems, the optimal treatment of herpes zoster requires early antiviral therapy and careful pain management. For patients who develop PHN, evidence-based pharmacotherapy using topical lidocaine patch, gabapentin, pregabalin, tricyclic antidepressants, and/or opiates can reduce pain burden. The live attenuated zoster vaccine is effective in reducing pain burden and preventing herpes zoster and PHN in older adults.
KeywordsHerpes zoster; varicella-zoster virus; postherpetic neuralgia; elderly; aged
IntroductionHerpes zoster is a neurocutaneous disease that is caused by the reactivation of varicellazoster virus (VZV) from a latent infection of dorsal sensory or cranial nerve ganglia following primary infection with VZV earlier in life. VZV is a double-stranded DNA herpesvirus with a genome that contains at least 70 gene products (1). VZV expresses gene products and attempts replication throughout life but cellular immunity is critical to containing VZV. With aging-related decline in cellular immunity to VZV, the virus may escape cell-mediated immune containment and spread in the affected ganglia and sensory nerves to the skin.Address correspondence to Dr. Schmader at 182 GRECC, Durham Veterans Affairs Medical Center, Durham, North Carolina, USA, telephone: 919-286-6932, fax: 919-286-6823, kenneth.schmader@duke.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author Manuscript Author ManuscriptAuthor Manuscript Author Manuscript
EpidemiologyThe estimated incidence of herpes zoster in persons older than 65 years old varies from approximately 10 to 14 cases per 1000 per year (2-4). The lifetime incidence of herpes zoster is estimated to be about 20-30% in the general population and maybe as high as 50% among those surviving to 85 years or higher (5). Current population figures and herpes zoster incidence data yield estimates of about 1 million new cases of herpes zoster each year in the United States (6). The incidence of recurrent herpes zoster is not as well established but the frequency of recurrent events is hig...